305 related articles for article (PubMed ID: 7906999)
21. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
22. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation.
Lowis SP; Pearson AD; Newell DR; Cole M
Cancer Res; 1993 Oct; 53(20):4881-9. PubMed ID: 8402676
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of intraperitoneally administered dipyridamole in cancer patients.
Chan TC; Coppoc GL; Zimm S; Cleary S; Howell SB
Cancer Res; 1988 Jan; 48(1):215-8. PubMed ID: 3334996
[TBL] [Abstract][Full Text] [Related]
24. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
[TBL] [Abstract][Full Text] [Related]
25. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia.
Plard C; Bressolle F; Fakhoury M; Zhang D; Yacouben K; Rieutord A; Jacqz-Aigrain E
Cancer Chemother Pharmacol; 2007 Sep; 60(4):609-20. PubMed ID: 17195068
[TBL] [Abstract][Full Text] [Related]
26. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates.
Blaney SM; Cole DE; Balis FM; Godwin K; Poplack DG
Cancer Res; 1993 Feb; 53(4):725-7. PubMed ID: 8428353
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial and pharmacokinetic evaluation of fazarabine in children.
Heideman RL; Gillespie A; Ford H; Reaman GH; Balis FM; Tan C; Sato J; Ettinger LJ; Packer RJ; Poplack DG
Cancer Res; 1989 Sep; 49(18):5213-6. PubMed ID: 2475244
[TBL] [Abstract][Full Text] [Related]
28. Etoposide pharmacokinetics in children treated for acute myeloid leukemia.
Palle J; Frost BM; Gustafsson G; Hellebostad M; Kanerva J; Liliemark E; Schmiegelow K; Lönnerholm G;
Anticancer Drugs; 2006 Oct; 17(9):1087-94. PubMed ID: 17001183
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
Mao ZL; Stalker D; Keirns J
Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
[TBL] [Abstract][Full Text] [Related]
30. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia.
Santana VM; Mirro J; Harwood FC; Cherrie J; Schell M; Kalwinsky D; Blakley RL
J Clin Oncol; 1991 Mar; 9(3):416-22. PubMed ID: 1671875
[TBL] [Abstract][Full Text] [Related]
31. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
Tamura K
Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies.
Rubnitz JE; Razzouk BI; Srivastava DK; Pui CH; Ribeiro RC; Santana VM
Leuk Res; 2004 Apr; 28(4):349-52. PubMed ID: 15109533
[TBL] [Abstract][Full Text] [Related]
33. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
[TBL] [Abstract][Full Text] [Related]
34. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.
Santana VM; Mirro J; Kearns C; Schell MJ; Crom W; Blakley RL
J Clin Oncol; 1992 Mar; 10(3):364-70. PubMed ID: 1346800
[TBL] [Abstract][Full Text] [Related]
35. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
Ueda T; Kamiya K; Urasaki Y; Wataya S; Kawai Y; Tsutani H; Sugiyama M; Nakamura T
Cancer Res; 1994 Jan; 54(1):109-13. PubMed ID: 8261429
[TBL] [Abstract][Full Text] [Related]
36. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Giles F; Fischer T; Cortes J; Garcia-Manero G; Beck J; Ravandi F; Masson E; Rae P; Laird G; Sharma S; Kantarjian H; Dugan M; Albitar M; Bhalla K
Clin Cancer Res; 2006 Aug; 12(15):4628-35. PubMed ID: 16899611
[TBL] [Abstract][Full Text] [Related]
37. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
[TBL] [Abstract][Full Text] [Related]
39. Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia.
Palle J; Frost BM; Peterson C; Gustafsson G; Hellebostad M; Kanerva J; Schmiegelow K; Lönnerholm G;
Anticancer Drugs; 2006 Apr; 17(4):385-92. PubMed ID: 16549995
[TBL] [Abstract][Full Text] [Related]
40. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia.
Yang L; Panetta JC; Cai X; Yang W; Pei D; Cheng C; Kornegay N; Pui CH; Relling MV
J Clin Oncol; 2008 Apr; 26(12):1932-9. PubMed ID: 18421047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
